RHJA
XERS icon

Rice Hall James & Associates’s Xeris Biopharma Holdings XERS Stock Holding History

Rice Hall James & Associates’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.46M Buy
+251,066
New +$1.66M 0.08% 187

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rice Hall James & Associates's XERS Position: Q1 2026 in Review

Rice Hall James & Associates opened a new position in Xeris Biopharma Holdings (XERS) in Q1 2026: 251,066 shares worth $1.46M. The stake represents 0.08% of the portfolio and ranks #187 among its holdings.

237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Rice Hall James & Associates held 251,066 shares of Xeris Biopharma Holdings worth $1.46M as of Q1 2026.
  • Xeris Biopharma Holdings was a new Rice Hall James & Associates position in Q1 2026.
  • Xeris Biopharma Holdings made up 0.08% of Rice Hall James & Associates's portfolio in Q1 2026, its #187 holding.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.